Salix issues $600 million in cheap new convertible debt
This article was originally published in Scrip
Executive Summary
Salix Pharmaceuticals, The Raleigh, North Carolina-based speciality pharma firm focused on gastro-intestinal therapies, has announced its plans to raise $600 million in debt (convertible notes), with the potential for a further $90 million over-allotments. The debt will attract only 1.5% interest.